Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)
Cartesian Therapeutics (RNAC) reported Tax Provisions of -$288000.0 for Q4 2022, down 308.7% year-over-year from $138000.0 in Q4 2021, and up 10.28% quarter-over-quarter from -$321000.0 in Q3 2022.
Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022) Analysis & Trends
Cartesian Therapeutics (RNAC) has 2 years of Tax Provisions data on file, last reported at -$288000.0 in Q4 2022.
- Tax Provisions for Q4 2022 came in at -$288000.0, down 308.7% year-over-year; the trailing twelve-month figure through Dec 2022 was $15.4 million (down 3.81% YoY), and the FY2025 annual result was -$9.2 million, down 3164.33% from the prior year.
- Tax Provisions grew to -$288000.0 in Q4 2022 per RNAC's latest filing, from -$321000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $15.8 million in Q3 2021 and troughed at -$321000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -288,000.00 |
| Sep 30, 2022 | -321,000.00 |
| Dec 31, 2021 | 138,000.00 |
| Sep 30, 2021 | 15.83 Mn |